基于系统生物学的肠菌移植在新型冠状病毒肺炎中的应用展望

doi:10.3760/cma.j.issn.1007-1245.2023.06.002

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (6): 745-749.DOI: 10.3760/cma.j.issn.1007-1245.2023.06.002

基于系统生物学的肠菌移植在新型冠状病毒肺炎中的应用展望

顾家博^1,2孟君¹ 常有¹ 金黑鹰³ 刘建磊³

¹连云港市中医院肛肠科，连云港　222004；²南京中医药大学，南京　210029；³江苏省第二中医院肛肠科，南京　210017

收稿日期:2022-11-09 出版日期:2023-03-15 发布日期:2023-04-02
通讯作者: 刘建磊，Email：736857385@qq.com
基金资助:
江苏省中医药管理局面上项目（MS2021030）

Fecal microbiota transplantation based on systemic biology in treatment of COVID-19

Gu Jiabo^1,2, Meng Jun¹, Chang You¹, Jin Heiying³, Liu Jianlei³

¹Lianyungang Hospital of Traditional Chinese Medicine, Lianyungang 222004, China; ²Nanjing University of Chinese Medicine, Nanjing 210029, China; ³Jiangsu Provincial Second Chinese Medicine Hospital, Nanjing 210017, China

Received:2022-11-09 Online:2023-03-15 Published:2023-04-02
Contact: Liu Jianlei, Email: 736857385@qq.com
Supported by:
Project Supported by Jiangsu Provincial Administration of Traditional Chinese Medicine (MS2021030)

摘要/Abstract

摘要：

目前还没有针对由严重急性呼吸综合征冠状病毒2型引起的新型冠状病毒肺炎的特效药物或治疗方法。本文通过研究新型冠状病毒肺炎、肠道菌群及免疫系统之间的关系及肠道菌群影响新型冠状病毒肺炎的相关机制，探究粪菌移植在新型冠状病毒肺炎治疗中的应用前景，以期为治疗新型冠状病毒肺炎提供新的方法。

关键词:

粪菌移植, 新型冠状病毒肺炎, 肠道菌群

Abstract:

There is no specific drug or treatment for COVID-19 caused by SARSCoV-2 currently. In this paper, by studying the relationship between COVID-19, intestinal flora, and immune system, and the related mechanism of intestinal flora affecting COVID-19, fecal microbiota transplantation in the treatment of COVID-19 is explored so as to provide new methods for the treatment of COVID-19.

Key words:

Fecal microbiota transplantation, COVID-19, Intestinal flora

顾家博孟君常有金黑鹰刘建磊.

基于系统生物学的肠菌移植在新型冠状病毒肺炎中的应用展望 [J]. 国际医药卫生导报, 2023, 29(6): 745-749.

Gu Jiabo, Meng Jun, Chang You, Jin Heiying, Liu Jianlei.

Fecal microbiota transplantation based on systemic biology in treatment of COVID-19 [J]. International Medicine and Health Guidance News, 2023, 29(6): 745-749.

参考文献

[1] Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic [J]. Acta Biomed, 2020, 91(1): 157-160. DOI: 10.23750/abm.v91i1.9397.
[2] Wang H, Wang H, Sun Y, et al. Potential associations between microbiome and COVID-19 [J]. Front Med (Lausanne), 2021, 8:785496. DOI: 10.3389/fmed.2021. 785496.
[3] 中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第八版　修订版)[J]. 中华临床感染病杂志,2021,14(2):81-88. DOI:10.3760/cma.j.issn.1674-2397. 2021.02.001.
[4] Yu J, Azzam EI, Jadhav AB, et al. COVID-19: the disease, the immunological challenges, the treatment with pharmaceuticals and low-dose ionizing radiation [J]. Cells, 2021, 10(9): 2212. DOI: 10.3390/cells10092212.
[5] Mortazavi SMJ, Kefayat A, Cai J. Point/Counterpoint. Low-dose radiation as a treatment for COVID-19 pneumonia: a threat or real opportunity? [J]. Med Phys, 2020, 47(9): 3773-3776. DOI: 10.1002/mp.14367.
[6] Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia [J]. Aging Dis, 2020, 11(2): 216-228. DOI: 10.14336/AD.2020.0228.
[7] Harrell CR, Sadikot R, Pascual J, et al. Mesenchymal stem cell-based therapy of inflammatory lung diseases: current understanding and future perspectives [J]. Stem Cells Int, 2019: 4236973. DOI: 10.1155/2019/4236973.
[8] Majumder J, Minko T. Recent developments on therapeutic and diagnostic approaches for COVID-19 [J]. AAPS J, 2021, 23(1): 14. DOI: 10.1208/s12248-020- 00532-2.
[9] Gartner Ⅲ TE, Jayaraman A. Modeling and simulations of polymers: a roadmap[J]. Macromolecules, 2019, 52(3): 755-786.
[10] McNeil SE. Unique benefits of nanotechnology to drug delivery and diagnostics//Characterization of nanoparticles intended for drug delivery[M]. California: Humana Press, 2011: 3-8.
[11] Hashimoto T, Perlot T, Rehman A, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation [J]. Nature, 2012, 487(7408): 477-481. DOI: 10.1038/nature11228.
[12] Keely S, Talley NJ, Hansbro PM. Pulmonary-intestinal cross-talk in mucosal inflammatory disease [J]. Mucosal Immunol, 2012, 5(1): 7-18. DOI: 10.1038/mi.2011.55.
[13] Zuo T, Zhang F, Lui GCY, et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization [J]. Gastroenterology, 2020, 159(3):944-955.e8. DOI: 10.1053/j.gastro.2020.05.048.
[14] Gu S, Chen Y, Wu Z, et al. Alterations of the gut microbiota in patients with coronavirus disease 2019 or H1N1 influenza [J]. Clin Infect Dis, 2020, 71(10): 2669-2678. DOI: 10.1093/cid/ciaa709.
[15] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [J]. Lancet, 2020, 395(10223): 497-506. DOI: 10.1016/S0140-6736(20)30183-5.
[16] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [J]. Lancet, 2020, 395(10223):507-513. DOI: 10.1016/S0140-6736(20)30211-7.
[17] Liang W, Feng Z, Rao S, et al. Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus [J]. Gut, 2020, 69(6): 1141-1143. DOI: 10.1136/gutjnl- 2020-320832.
[18] Carfì A, Bernabei R, Landi F, et al. Persistent symptoms in patients after acute COVID-19 [J]. JAMA, 2020, 324(6): 603-605. DOI: 10.1001/jama.2020.12603.
[19] Shi N, Li N, Duan X, et al. Interaction between the gut microbiome and mucosal immune system [J]. Mil Med Res, 2017, 4:14. DOI: 10.1186/s40779-017-0122-9.
[20] Berg D, Clemente JC, Colombel JF. Can inflammatory bowel disease be permanently treated with short-term interventions on the microbiome? [J]. Expert Rev Gastroenterol Hepatol, 2015, 9(6):781-795. DOI: 10.1586/17474124.2015.1013031.
[21] Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease [J]. Cell Res, 2020, 30(6): 492-506. DOI: 10.1038/s41422-020- 0332-7.
[22] Atyeo C, Fischinger S, Zohar T, et al. distinct early serological signatures track with SARS-CoV-2 survival [J]. Immunity, 2020, 53(3):524-532.e4. DOI: 10.1016/j.immuni.2020.07.020.
[23] Kuri-Cervantes L, Pampena MB, Meng W, et al. Comprehensive mapping of immune perturbations associated with severe COVID-19 [J]. Sci Immunol, 2020, 5(49): eabd7114. DOI: 10.1126/sciimmunol.abd7114.
[24] B Bermejo-Martin JF, González-Rivera M, Almansa R, et al. Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19 [J]. Crit Care, 2020, 24(1):691. DOI: 10.1186/s13054-020- 03398-0.
[25] Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor [J]. Cell, 2020, 181(2): 271-280.e8. DOI: 10.1016/j.cell.2020.02.052.
[26] Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 [J]. Science, 2020, 367(6485):1444-1448. DOI: 10.1126/science.abb2762.
[27] Wang K, Gheblawi M, Oudit GY. Angiotensin converting enzyme 2: a double-edged sword [J]. Circulation, 2020, 142(5):426-428. DOI: 10.1161/CIRCULATIONAHA. 120.047049.
[28] Gu X, Lu Q, Zhang C, et al. Clinical application and progress of fecal microbiota transplantation in liver diseases: a review [J]. Semin Liver Dis, 2021, 41(4):495-506. DOI: 10.1055/s-0041-1732319.
[29] Dhar D, Mohanty A. Gut microbiota and Covid-19- possible link and implications [J]. Virus Res, 2020, 285: 198018. DOI: 10.1016/j.virusres.2020.198018.
[30] Green DR, Galluzzi L, Kroemer G. Mitochondria and the autophagy-inflammation-cell death axis in organismal aging [J]. Science, 2011, 333(6046): 1109-1112. DOI: 10.1126/science.1201940.
[31] Sharma L, Riva A. Intestinal barrier function in health and disease-any role of SARS-CoV-2? [J]. Microorganisms, 2020, 8(11): 1744. DOI: 10.3390/microorganisms 8111744.
[32] de Groot P, Nikolic T, Pellegrini S, et al. Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial [J]. Gut, 2021, 70(1): 92-105. DOI: 10.1136/gutjnl-2020-322630.
[33] Vendrik KEW, Ooijevaar RE, de Jong PRC, et al. Fecal microbiota transplantation in neurological disorders [J]. Front Cell Infect Microbiol, 2020, 10: 98. DOI: 10.3389/fcimb.2020.00098.
[34] Amoroso C, Perillo F, Strati F, et al. The role of gut microbiota biomodulators on mucosal immunity and intestinal inflammation [J]. Cells, 2020, 9(5): 1234. DOI: 10.3390/cells9051234.
[35] Cammarota G, Ianiro G, Kelly CR, et al. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice [J]. Gut, 2019, 68(12): 2111-2121. DOI: 10.1136/gutjnl-2019-319548.
[36] Keller JJ, Ooijevaar RE, Hvas CL, et al. A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group [J]. United European Gastroenterol J, 2021, 9(2): 229-247. DOI: 10.1177/2050640620967898.
[37] Mullish BH, Quraishi MN, Segal JP, et al. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines [J]. Gut, 2018, 67(11):1920-1941. DOI: 10.1136/gutjnl-2018-316818.
[38] Jarmo O, Veli-Jukka A, Eero M. Treatment of Clostridioides (Clostridium) difficile infection[J]. Annals Med, 2020, 52(1-2): 12-20.
[39] Zuo T, Wong SH, Lam K, et al. Bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile infection is associated with treatment outcome [J]. Gut, 2018, 67(4):634-643. DOI: 10.1136/gutjnl-2017-313952.
[40] Kelly CR, Yen EF, Grinspan AM, et al. Fecal microbiota transplantation is highly effective in real-world practice: initial results from the FMT national registry [J]. Gastroenterology, 2021, 160(1):183-192.e3. DOI: 10.1053/j.gastro.2020.09.038.
[41] Prescott HC, Dickson RP, Rogers MA, et al. Hospitalization type and subsequent severe sepsis [J]. Am J Respir Crit Care Med, 2015, 192(5):581-588. DOI: 10.1164/rccm.201503-0483OC.
[42] Haak BW, Wiersinga WJ. The role of the gut microbiota in sepsis [J]. Lancet Gastroenterol Hepatol, 2017, 2(2): 135-143. DOI: 10.1016/S2468-1253(16)30119-4.
[43] Kim SM, DeFazio JR, Hyoju SK, et al. Fecal microbiota transplant rescues mice from human pathogen mediated sepsis by restoring systemic immunity [J]. Nat Commun, 2020, 11(1): 2354. DOI: 10.1038/s41467-020-15545-w.
[44] Li S, Lv J, Li J, et al. Intestinal microbiota impact sepsis associated encephalopathy via the vagus nerve [J]. Neurosci Lett, 2018, 662:98-104. DOI: 10.1016/j.neulet.2017.10.008.
[45] Haak BW, Prescott HC, Wiersinga WJ. Therapeutic potential of the gut microbiota in the prevention and treatment of sepsis [J]. Front Immunol, 2018, 9: 2042. DOI: 10.3389/fimmu.2018.02042.
[46] Gai X, Wang H, Li Y, et al. Fecal Microbiota transplantation protects the intestinal mucosal barrier by reconstructing the gut microbiota in a murine model of sepsis [J]. Front Cell Infect Microbiol, 2021, 11: 736204. DOI: 10.3389/fcimb.2021.736204.
[47] Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities [J]. Nat Rev Microbiol, 2012, 10(9): 655-666. DOI: 10.1038/nrmicro2848.
[48] Chang PV, Hao L, Offermanns S, et al. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition [J]. Proc Natl Acad Sci U S A, 2014, 111(6): 2247-2252. DOI: 10.1073/pnas.1322269111.
[49] Serrano-Villar S, Talavera-Rodríguez A, Gosalbes MJ, et al. Fecal microbiota transplantation in HIV: a pilot placebo-controlled study [J]. Nat Commun, 2021, 12(1):1139. DOI: 10.1038/s41467-021-21472-1.

基于系统生物学的肠菌移植在新型冠状病毒肺炎中的应用展望

Fecal microbiota transplantation based on systemic biology in treatment of COVID-19

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics